Boston MA 转移性癌症临床试验
63项针对 转移性癌症的研究正在 Boston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Boston
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
招募中1 期
- Dana-Farber Cancer Institute, Boston
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- Dana Farber Cancer Institute, Boston
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Insitute, Boston
A Study of ASP3082 in Adults With Advanced Solid Tumors
招募中1 期
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
招募中2/3 期
- Dana-Farber Cancer Institute, Boston
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
招募中3 期
- Brigham and Women's Hospital (BWH), Boston
- Dana-Farber Cancer Institute (DFCI), Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
招募中1/2 期
- Dana Farber Cancer Institute., Boston
A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
招募中1/2 期
- Mass General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
招募中1 期
- Mass General Cancer Center, Boston
Pemigatinib + Afatinib in Advanced Refractory Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
招募中1 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
招募中3 期
- Massachusetts General Hospital, Boston
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
招募中3 期
- Mass General Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- Dana Farber Cancer Institute, Boston
A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
招募中1/2 期
- Massachusetts General Hospital - Main Campus, Boston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
招募中1/2 期
- Brigham and Women's Hospital, Boston
- Dana Farber/Mass General Brigham Cancer Care, Inc, Boston
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- Boston Medical Center, Boston
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
招募中1 期
- Dana-Farber Cancer Institute, Boston
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
招募中2 期
- Dana-Farber Cancer Institute, Boston
AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Boston
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
招募中1/2 期
- Massachusetts General Hospital, Boston
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
招募中1 期
- Massachusetts General Hospital (MG), Boston
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- Dana-Farber Cancer Institute, Boston
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
招募中1 期
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
招募中1 期
- Massachusetts General Hospital, Boston
FOG-001 in Locally Advanced or Metastatic Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
招募中1 期
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
招募中1 期
- Dana-Farber Cancer Institute, Boston
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
招募中1 期
- Dana-Farber Cancer Institute, Boston
A Study of PYX-201 in Advanced Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation
招募中1 期
- Mass General Brigham Cancer Institute at Massachusetts General Hospital, Boston
A Study of XB628 Alone and in Combination With Zanzalintinib in Participants With Recurrent Advanced or Metastatic Solid Tumors
招募中1 期
- Exelixis Clinical Site #10, Boston
- Exelixis Clinical Site #11, Boston
A Study of LY4175408 in Participants With Advanced Cancer
招募中1 期
- Massachusetts General Hospital, Boston
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
招募中1 期
- Research Site, Boston
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
招募中1 期
- Research Site, Boston
- Research Site, Boston
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
招募中1 期
- Massachusetts General Hospital, Boston
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
招募中1/2 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
招募中3 期
- Massachusetts General Hospital Cancer Center, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
招募中2 期
- I-Mab Site 1002, Boston
Remote Monitoring and Symptom Management Digital Application
招募中
- Massachusetts General Hospital, Boston
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
招募中1/2 期
- Massachusetts General Hospital, Boston
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
招募中2/3 期
- Dana-Farber Cancer Institute, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
招募中3 期
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
招募中2/3 期
- VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
招募中2/3 期
- Massachusetts General Hospital, Boston
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
Venetoclax Basket Trial for High Risk Hematologic Malignancies
招募中1 期
- Dana-Farber Cancer Institute, Boston
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
招募中
- Massachusetts General Hospital, Boston
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
招募中1 期
- Massachusetts General Hospital, Boston
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
招募中1 期
- Mass General Hospital, Boston
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
招募中1 期
- Massachusetts General Hospital, Boston
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
招募中3 期
- Dana-Farber Cancer Institute, Boston
IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures
招募中观察性研究
- Massachusetts General Hospital, Boston
Comprehensive Outcomes for After Cancer Health
招募中欢迎健康志愿者
- Dana Farber Cancer Institute, Boston
其他城市的 转移性癌症试验
- Houston, TX104 项研究
- New York City, NY93 项研究
- Nashville, TN70 项研究
- Los Angeles, CA57 项研究
- St. Louis, MO54 项研究
- Arlington, VA53 项研究
- Philadelphia, PA46 项研究
- Chicago, IL45 项研究
- San Antonio, TX44 项研究
- Washington, DC43 项研究
- Dallas, TX42 项研究
- Seattle, WA39 项研究
Boston的其他研究
- 乳腺癌112 项研究
- 非小细胞肺癌90 项研究
- 癌症（所有类型）85 项研究
- 结直肠癌63 项研究
- 肺癌62 项研究
- 卵巢癌61 项研究
- 前列腺癌59 项研究
- 抑郁症52 项研究
- 子宫内膜癌50 项研究
- 心力衰竭44 项研究
- 急性髓系白血病44 项研究
- 胰腺癌43 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。